State Street SPDR S&P Pharmaceuticals ETF
XPH
82 hedge funds and large institutions have $235M invested in State Street SPDR S&P Pharmaceuticals ETF in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 8 closing their positions.
171% more call options, than puts
Call options by funds: $2.15M | Put options by funds: $795K
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
63% more capital invested
Capital invested by funds: $144M → $235M (+$91.3M)
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
13.63% more ownership
Funds ownership: 62.63% → 76.26% (+14%)
6% more funds holding
Funds holding: 77 → 82 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$40.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$25.4M |
| 3 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$16.5M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$11M |
| 5 |
Morgan Stanley
New York
|
+$8.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$5.91M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$5.01M |
| 3 |
LPL Financial
San Diego,
California
|
-$3.42M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.67M |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$1.32M |
XPH Hedge Fund Activity: Q1 2026 in Review
82 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2026, worth a combined $235M — up 63% from $144M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new XPH positions and 8 closed out — a net gain of 8 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was Carson Wealth (CWM LLC), adding an estimated $40.5M. The largest seller was Citigroup, cutting an estimated $5.91M.
- 82 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2026, up from 77 in Q4 2025.
- Funds reported $235M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2026, up 63% quarter-over-quarter.
- 16 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2026 and 8 closed out, a net change of +8 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2026 was Carson Wealth (CWM LLC), an estimated $40.5M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2026 was Citigroup, an estimated $5.91M sold.
Based on aggregated 13F filings for Q1 2026.